PROTOCOL SPECIFIC RESEARCH RESOURCE

特定于协议的研究资源

• 批准号: 8637172
• 负责人: Edward P Gelmann
• 金额: $ 13.64万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-07-04 至 2014-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8637172
• 关键词: Basic Science; Breast Lymphoma; Budgets; Cancer Center Support Grant; Cancer Vaccines; Clinic; Clinical Research; Clinical Trials; Consent; Continuing Education; Data; Developmental Therapeutics Program; Eligibility Determination; Enrollment; Evaluation; Funding; Grant; Herbert Irving Comprehensive Cancer Center; Insurance; Medical; Methods; Nursing Research; Office Management; Office Nursing; Patient Care; Patients; Peer Review; Pharmacologic Substance; Phase; Phase I Clinical Trials; Protocols documentation; Reporting; Research; Research Personnel; Research Support; Resources; Series; Services; Technology; Testing; Toxic effect; cancer immunotherapy; cancer therapy; clinical efficacy; data management; innovation; malignant breast neoplasm; novel; oncology; phase 1 study; programs; success; therapy development; translational study; treatment trial

The Herbert Irving Comprehensive Cancer Center participates in a wide range of innovative, feasibility or proof of principle trials originating from its research programs and initiated by institutional Pis. Enrollment in these studies has been maintained throughout the last grant period. The conduct of these studies is supported by research nursing and data management provided by the Clinical Research Management Office (CRMO). Research Nursing focuses solely on the eligibility, consenting and management of patients on clinical trials. In addition to its participation in the scope of high-priority clinical trials, Herbert Irving Comprehensive Cancer Center has conducted a series of innovative phase I trials of cancer vaccines and immunotherapy that have provided important information on the mechanisms and clinical efficacy of these agents. There is an increasing emphasis on interaction between basic science and clinical research as exemplified by ongoing translational studies in breast cancer and lymphoma. Expanded support for our participation in high priority and innovative trials is requested. The projected operating budget for Protocol Specific Research Support is $352,247, of which we are requesting 100% support from the CCSG.

赫伯特·欧文综合癌症中心参与了一系列广泛的创新、可行性或 源自其研究项目并由机构 Pis 发起的原理试验证明。报名参加 这些研究在上一个拨款期间一直得到维持。这些研究的进行是 由临床研究管理提供的研究护理和数据管理支持 办公室（CRMO）。研究护理仅关注患者的资格、同意和管理 在临床试验上。除了参与高优先级临床试验范围外，赫伯特·欧文 (Herbert Irving) 综合癌症中心开展了一系列创新的癌症疫苗和I期试验 免疫疗法提供了有关这些机制和临床疗效的重要信息 代理。人们越来越重视基础科学与临床研究之间的相互作用 正在进行的乳腺癌和淋巴瘤转化研究就是例证。扩大对我们的支持 要求参与高度优先和创新的试验。 协议特定研究支持的预计运营预算为 352,247 美元，其中我们 请求 CCSG 100% 支持。